1. Effects of purified anthocyanin supplementation on platelet chemokines in hypocholesterolemic individuals: a randomized controlled trial.
- Author
-
Xiandan Zhang, Yanna Zhu, Fenglin Song, Yanling Yao, Fuli Ya, Dan Li, Wenhua Ling, and Yan Yang
- Subjects
- *
ATHEROSCLEROSIS prevention , *ANALYSIS of covariance , *ANTHROPOMETRY , *BIOMARKERS , *C-reactive protein , *CHEMOKINES , *CONFIDENCE intervals , *STATISTICAL correlation , *DIETARY supplements , *ENZYME-linked immunosorbent assay , *FLAVONOIDS , *HYPERCHOLESTEREMIA , *INTERLEUKINS , *LIPIDS , *LOW density lipoproteins , *PLACEBOS , *RESEARCH funding , *T-test (Statistics) , *RANDOMIZED controlled trials , *BLIND experiment , *DATA analysis software , *DESCRIPTIVE statistics - Abstract
Background: It is becoming increasingly evident that platelet chemokines are involved in distinct aspects of atherosclerosis. The aim of this study was to examine the effects of long-term supplementation with purified anthocyanins on platelet chemokines in hypercholesterolemic individuals and to identify correlations of decreased platelet chemokine levels with serum lipid and inflammatory marker levels. Methods: A total of 146 hypercholesterolemic individuals were recruited and treated with 320 mg of purified anthocyanins (n = 73) or a placebo (n = 73) daily for 24 weeks in this randomized, double-blind, placebo-controlled trial. Results: Anthocyanin supplementation for 24 weeks significantly decreased the plasma CXCL7 (-12.32% vs. 4.22%, P =0 . 001), CXCL5 (-9.95% vs. 1.93%, P = 0.011), CXCL8 (-6.07% vs. 0.66%, P = 0.004), CXCL12 (-8.11% vs. 5.43%, P = 0.023) and CCL2 levels (-11.63% vs. 12.84%, P = 0.001) compared with the placebo. Interestingly, the decreases in the CXCL7 and CCL2 levels were both positively correlated with the decreases in the serum low-density lipoprotein-cholesterol (LDL-C), high-sensitivity C-reactive protein (hsCRP) and interleukin-1β (IL-1β) levels after anthocyanin supplementation for 24 weeks. The decrease in the CXCL8 level was negatively correlated with the increase in the how-density lipoprotein- cholesterol (HDL-C) level and was positively correlated with the decrease in the soluble P-selectin (sP-selectin) level in the anthocyanin group. In addition, a positive correlation was observed between the decreases in the CXCL12 and tumornecrosis factor-α (TNF-α) levels after anthocyanin supplementation. However, the plasma CXCL4L1, CXCL1, macrophage migration inhibitory factor (MIF) and human plasminogen activator inhibitor 1 (PAI-1) levels did not significantly change following anthocyanin supplementation. Conclusions: The present study supports the notion that platelet chemokines are promising targets of anthocyanins in the prevention of atherosclerosis. Trial registration: ChiCTR-TRC-08000240. Registered: 10 December 2008. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF